4371.30 -2.70 (-0.06%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
4338.0
Today’s High
4375.8
52 Week Low
3655.0
52 Week High
4930.0
4372.15 -2.05 (-0.05%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
4336.8
Today’s High
4377.45
52 Week Low
3654
52 Week High
4931.05
Key Metrics
- Market Cap (In Cr) 74381.13
- Beta 0.19
- Div. Yield (%) 0.67
- P/B 3.87
- TTM P/E 23.14
- Peg Ratio 1.21
- Sector P/E 27.15
- D/E 0.08
- Open Price 4374
- Prev Close 4374
Analysis
Price Analysis
-
1 Week1.76%
-
3 Months6.29%
-
6 Month4.03%
-
YTD-8.71%
-
1 Year-2.55%
Risk Meter
- 20% Low risk
- 20% Moderate risk
- 20% Balanced Risk
- 20% High risk
- 20% Extreme risk
Recos
39 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 1
- Sell
- 1
- Hold
- 5
- Buy
- 16
- Strong Buy
- 16
Dr Reddys Laboratories News
Sputnik V vaccine will be available in these 9 Indian cities soon. Details here
1 min read . 17 Jun 2021Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 21545.2
- Selling/ General/ Admin Expenses Total
- 7339.9
- Depreciation/ Amortization
- 1165.2
- Total Operating Expense
- 18942.7
- Operating Income
- 2602.5
- Net Income Before Taxes
- 3061.4
- Net Income
- 2182.5
- Diluted Normalized EPS
- 165.95
- Period
- 2022
- Total Assets
- 29746.9
- Total Liabilities
- 10534.5
- Total Equity
- 19212.4
- Tangible Book Valueper Share Common Eq
- 961.93
- Period
- 2022
- Cashfrom Operating Activities
- 2810.8
- Cashfrom Investing Activities
- -2638.7
- Cashfrom Financing Activities
- -242.2
- Net Changein Cash
- 3.2
- Period
- 2021
- Total Revenue
- 19047.5
- Selling/ General/ Admin Expenses Total
- 6385.1
- Depreciation/ Amortization
- 1228.8
- Total Operating Expense
- 16402.2
- Operating Income
- 2645.3
- Net Income Before Taxes
- 2883.5
- Net Income
- 1951.6
- Diluted Normalized EPS
- 142.73
- Period
- 2021
- Total Assets
- 26616.8
- Total Liabilities
- 8975.1
- Total Equity
- 17641.7
- Tangible Book Valueper Share Common Eq
- 818.04
- Period
- 2021
- Cashfrom Operating Activities
- 3570.3
- Cashfrom Investing Activities
- -2266
- Cashfrom Financing Activities
- -29.8
- Net Changein Cash
- 1285.8
- Period
- 2020
- Total Revenue
- 17517
- Selling/ General/ Admin Expenses Total
- 5881
- Depreciation/ Amortization
- 1163.1
- Total Operating Expense
- 16203
- Operating Income
- 1314
- Net Income Before Taxes
- 1885.7
- Net Income
- 2026
- Diluted Normalized EPS
- 187.62
- Period
- 2020
- Total Assets
- 23225.3
- Total Liabilities
- 7626.5
- Total Equity
- 15598.8
- Tangible Book Valueper Share Common Eq
- 749.67
- Period
- 2020
- Cashfrom Operating Activities
- 2984.1
- Cashfrom Investing Activities
- -492.3
- Cashfrom Financing Activities
- -2515.9
- Net Changein Cash
- -26.6
- Period
- 2019
- Total Revenue
- 15448.2
- Selling/ General/ Admin Expenses Total
- 5839.9
- Depreciation/ Amortization
- 1134.8
- Total Operating Expense
- 13404.8
- Operating Income
- 2043.4
- Net Income Before Taxes
- 2292
- Net Income
- 1950
- Diluted Normalized EPS
- 111.64
- Period
- 2019
- Total Assets
- 22465.6
- Total Liabilities
- 8442
- Total Equity
- 14023.6
- Tangible Book Valueper Share Common Eq
- 559.81
- Period
- 2019
- Cashfrom Operating Activities
- 2870.4
- Cashfrom Investing Activities
- -772.7
- Cashfrom Financing Activities
- -2132.6
- Net Changein Cash
- -31.4
- Period
- 2018
- Total Revenue
- 14281
- Selling/ General/ Admin Expenses Total
- 5670.3
- Depreciation/ Amortization
- 1077.2
- Total Operating Expense
- 13007
- Operating Income
- 1274
- Net Income Before Taxes
- 1350.4
- Net Income
- 946.8
- Diluted Normalized EPS
- 64.61
- Period
- 2018
- Total Assets
- 22544.3
- Total Liabilities
- 9972.7
- Total Equity
- 12571.6
- Tangible Book Valueper Share Common Eq
- 474.6
- Period
- 2018
- Cashfrom Operating Activities
- 1803
- Cashfrom Investing Activities
- -1488.3
- Cashfrom Financing Activities
- -444
- Net Changein Cash
- -123.6
- Period
- 2017
- Total Revenue
- 14196.1
- Selling/ General/ Admin Expenses Total
- 5605.4
- Depreciation/ Amortization
- 1026.6
- Total Operating Expense
- 12743.4
- Operating Income
- 1452.7
- Net Income Before Taxes
- 1553.7
- Net Income
- 1292.1
- Diluted Normalized EPS
- 81.14
- Period
- 2017
- Total Assets
- 21816.5
- Total Liabilities
- 9554.4
- Total Equity
- 12262.1
- Tangible Book Valueper Share Common Eq
- 461.23
- Period
- 2017
- Cashfrom Operating Activities
- 2144.5
- Cashfrom Investing Activities
- -1840.4
- Cashfrom Financing Activities
- -369.2
- Net Changein Cash
- -114.3
- Period
- 2022-09-30
- Total Revenue
- 6331.8
- Selling/ General/ Admin Expenses Total
- 2583.4
- Depreciation/ Amortization
- 309.2
- Total Operating Expense
- 4742.1
- Operating Income
- 1589.7
- Net Income Before Taxes
- 1613.6
- Net Income
- 1114.2
- Diluted Normalized EPS
- 67.08
- Period
- 2022-09-30
- Total Assets
- 29168.9
- Total Liabilities
- 8393.7
- Total Equity
- 20775.2
- Tangible Book Valueper Share Common Eq
- 1029.64
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 1593.6
- Cashfrom Investing Activities
- 81
- Cashfrom Financing Activities
- -2314.6
- Net Changein Cash
- -575.9
- Period
- 2022-06-30
- Total Revenue
- 5232.9
- Selling/ General/ Admin Expenses Total
- 2368.2
- Depreciation/ Amortization
- 301.8
- Total Operating Expense
- 4581.3
- Operating Income
- 651.6
- Net Income Before Taxes
- 1468
- Net Income
- 1189
- Diluted Normalized EPS
- 71.48
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 5474.9
- Selling/ General/ Admin Expenses Total
- 2384.2
- Depreciation/ Amortization
- 293
- Other Operating Expenses Total
- -6.7
- Total Operating Expense
- 5310.2
- Operating Income
- 164.7
- Net Income Before Taxes
- 258.9
- Net Income
- 97
- Diluted Normalized EPS
- 34.78
- Period
- 2022-03-31
- Total Assets
- 29746.9
- Total Liabilities
- 10534.5
- Total Equity
- 19212.4
- Tangible Book Valueper Share Common Eq
- 961.93
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 2810.8
- Cashfrom Investing Activities
- -2638.7
- Cashfrom Financing Activities
- -242.2
- Net Changein Cash
- 3.2
- Period
- 2021-12-31
- Total Revenue
- 5338.3
- Selling/ General/ Admin Expenses Total
- 2303.2
- Depreciation/ Amortization
- 294.2
- Total Operating Expense
- 4416.8
- Operating Income
- 921.5
- Net Income Before Taxes
- 974.2
- Net Income
- 709.3
- Diluted Normalized EPS
- 42.86
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 5786.9
- Selling/ General/ Admin Expenses Total
- 2399.5
- Depreciation/ Amortization
- 294.1
- Total Operating Expense
- 4721.2
- Operating Income
- 1065.7
- Net Income Before Taxes
- 1272.5
- Net Income
- 995.8
- Diluted Normalized EPS
- 59.88
- Period
- 2021-09-30
- Total Assets
- 27921
- Total Liabilities
- 9376.6
- Total Equity
- 18544.4
- Tangible Book Valueper Share Common Eq
- 889.27
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 165.8
- Cashfrom Investing Activities
- -163.8
- Cashfrom Financing Activities
- -495.1
- Net Changein Cash
- -484
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day4480.46
- 10 Day4440.56
- 20 Day4448.98
- 50 Day4395.06
- 100 Day4329.06
- 300 Day4258.78
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Cipla
- 1112.3
- 3.15
- 0.28
- 1185.2
- 850
- 90016.94
- Divis Laboratories
- 3350
- -6.1
- -0.18
- 4772.05
- 3197
- 89432.38
- Dr Reddys Laboratories
- 4371.3
- -2.7
- -0.06
- 4930
- 3655
- 74381.13
- Torrent Pharmaceuticals
- 1629.6
- 11.45
- 0.71
- 1722.7
- 1235.88
- 54824.78
- Abbott India
- 20217.15
- 9.5
- 0.05
- 20895
- 15426.74
- 42624.83
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Cipla
- 33.51
- 4.32
- 11.75
- 10.53
- Divis Laboratories
- 30.19
- 7.63
- 22.49
- 28.33
- Dr Reddys Laboratories
- 26.99
- 3.87
- 12.1
- 10.32
- Torrent Pharmaceuticals
- 50.55
- 9.21
- 16.36
- 10.81
- Abbott India
- 53.37
- 15.12
- 27.07
- 14.45
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 73.02%
- 121,556,924
- FIRST SENTIER INVESTORS ICVC - STEWART INVESTORS ASIA PACIFIC LEADERS SUSTAINABILITY FUND
- 2.2%
- 3,658,520
- GOVERNMENT OF SINGAPORE
- 1.86%
- 3,100,780
- KUWAIT INVESTMENT AUTHORITY FUND 601
- 1.14%
- 1,895,518
- GOVERNMENT PENSION FUND GLOBAL
- 1.01%
- 1,685,343
- Others
- 19.49%
- 32,436,274
- SBI-ETF NIFTY 50
- 2.63%
- 4,370,482
- ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE NIFTY ETF
- 1.56%
- 2,589,737
- ICICI PRUDENTIAL SENSEX INDEX FUND
- 1.46%
- 2,425,303
- HDFC TRUSTEE COMPANY LTD. A/C HDFC NIFTY 50 ETF
- 1.16%
- 1,924,536
- Others
- 6.03%
- 10,071,430
- LIFE INSURANCE CORPORATION OF INDIA P & GS FUND
- 7.58%
- 12,623,693
- ICICI PRUDENTIAL LIFE INSURANCE COMPANY LIMITED
- 1.14%
- 1,891,294
- Others
- 2.8%
- 4,682,815
- J P Morgan Chase Bank NA
- 10.08%
- 16,780,945
- Others
- 7.96%
- 13,245,506
- Trusts
- 1.81%
- 3,016,486
- NPS TRUST-A/C HDFC PENSION MANAGEMENT COMPANY LTD SCHEME TAX SAVER- TIER 2
- 1.8%
- 2,995,338
- Clearing Members
- 0.23%
- 380,676
- Unclaimed or Suspense or Escrow Account
- 0.21%
- 347,245
- HUF
- 0.17%
- 289,188
- Others
- 0.95%
- 1,581,067
- Others
- 0.56%
- 929,837
- Others
- 0.39%
- 647,004
- Others
- 0.23%
- 389,824
- Others
- 0.14%
- 230,305
- Others
- 0.1%
- 174,771
- Others
- 0.09%
- 146,876
- Others
- 0.02%
- 38,735
- Others
- 0%
- 2,334
- Others
- 0%
- 400
- Promoter & Promoter Group Shareholding
- 26.71%
- 44,461,128
- APS Trust
- 20.63%
- 34,345,308
- KALLAM SATISH REDDY HUF
- 3.32%
- 5,523,677
- GUNUPATI VENKATESWARA PRASAD(HUF)
- 1.53%
- 2,543,418
- SAMRAJYAM REDDY KALLAM
- 0.67%
- 1,120,499
- SATISH REDDY KALLAM
- 0.54%
- 901,002
- ANURADHA GUNUPATI
- 0.01%
- 9,205
- G VANI SANJANA REDDY
- 0%
- 5,140
- DEEPTI REDDY KALLAM
- 0%
- 5,140
- GUNUPATI MALLIKA REDDY
- 0%
- 5,139
- SHARATHCHANDRA REDDY GUNUPATI
- 0%
- 2,600
- Non Promoter - Non Public shareholder
- 0.27%
- 448,561
- Others
- 0.27%
- 448,561
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 28-Oct-22
- Quarterly Results
- 28-Jul-22
- Quarterly Results
- 19-May-22
- Audited Results & Final Dividend
- 28-Jan-22
- Quarterly Results
- 29-Oct-21
- Quarterly Results
- 27-Jul-21
- Quarterly Results
- 14-May-21
- Audited Results & Final Dividend
- 29-Jan-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 29-Jul-22
- 20-May-22
- AGM
- 29-Mar-22
- 25-Feb-22
- POM
- 28-Jul-21
- 20-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 19-May-22
- -
- 11-Jul-22
- 30
- 14-May-21
- -
- 09-Jul-21
- 25
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Dr Reddys Laboratories
- Industry Biotechnology & Drugs
- ISIN INE089A01023
- BSE Code 500124
- NSE Code DRREDDY
Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.
MANAGEMENT
- K. Satish Reddy Chairman of the Board
- G. V. Prasad Co-Chairman of the Board, Managing Director
- Erez Israeli Chief Executive Officer
- Parag Agarwal Chief Financial Officer
- Patrick Aghanian Chief Executive Officer, European Generics
- Marc Kikuchi Chief Executive Officer, North America Generics
- M. Ramana Chief Executive Officer, Branded Markets (India and Emerging Markets)
- Deepak Sapra Chief Executive Officer, API and Services
- Archana Bhaskar Chief Human Resource Officer
- Mukesh Rathi Chief Digital and Information Officer
Company Summary
DR REDDYS LABORATORIES SUMMARY
Dr Reddys Laboratories is trading 0.06% lower at Rs 4371.30 as compared to its last closing price. Dr Reddys Laboratories has been trading in the price range of 4375.8 & 4338.0. Dr Reddys Laboratories has given -8.71% in this year & 1.76% in the last 5 days.
Dr Reddys Laboratories has TTM P/E ratio 23.14 as compared to the sector P/E of 27.15. There are 39 analysts who have initiated coverage on Dr Reddys Laboratories. There are 16 analysts who have given it a strong buy rating & 16 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.
The company posted a net profit of 1114.2 Crores in its last quarter.
Listed peers of Dr Reddys Laboratories include Cipla (0.28%), Divis Laboratories (-0.18%), Dr Reddys Laboratories (-0.06%) etc.
FAQs about Dr Reddys Laboratories
Dr Reddys Laboratories is trading at 4371.30 as on 7 Dec, 2022 11:41:39 AM. This is -0.06% lower as compared to its previous closing price of 4374
The market capitalization of Dr Reddys Laboratories is 74381.13 Cr as on 7 Dec, 2022 11:41:39 AM.
The average broker rating on Dr Reddys Laboratories is Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong sell rating
- 1 analysts have given a sell rating
- 5 analysts have given a hold rating
- 16 analysts have given a buy rating
- 16 analysts have given a strong buy rating
The 52 wk high for Dr Reddys Laboratories is 4930.0 whereas the 52 wk low is 3655.0
Dr Reddys Laboratories can be analyzed on the following key metrics -
- TTM P/E: 23.14
- Sector P/E: 27.15
- Dividend Yield: 0.67%
- D/E ratio: -
Dr Reddys Laboratories reported a net profit of 2182.5 Cr in 2022.
